Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study (Q34690368)

4 August 2017

title

Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study (English)

1 reference

cost-effectiveness analysis

4 August 2017

main subject

1 reference

1 reference

1 reference

1 reference

5

Fred Poordad

0 references

author name string

Shannon Allen Ferrante

1

1 reference

4 August 2017

Jagpreet Chhatwal

2

1 reference

4 August 2017

Clifford A Brass

3

1 reference

4 August 2017

Antoine C El Khoury

4

1 reference

4 August 2017

Jean-Pierre Bronowicki

6

1 reference

4 August 2017

Elamin H Elbasha

7

1 reference

4 August 2017

language of work or name

1 reference

27 April 2013

1 reference

4 August 2017

published in

BMC Infectious Diseases

1 reference

4 August 2017

volume

13

1 reference

4 August 2017

page(s)

190

1 reference

Creative Commons Attribution 2.0 Generic

4 August 2017

copyright license

start time

27 April 2013

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Chronic hepatitis C virus (HCV) disease burden and cost in the United States

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3643851

New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3643851

The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3643851

Economic burden of hepatitis C-associated diseases in the United States.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3643851

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3643851

All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3643851

Telaprevir for retreatment of HCV infection

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3643851

Telaprevir for previously untreated chronic hepatitis C virus infection

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3643851

Boceprevir for previously treated chronic HCV genotype 1 infection

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3643851

Boceprevir for untreated chronic HCV genotype 1 infection

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3643851

Hepatitis C: diagnosis and treatment

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3643851

Epidemiology of hepatitis B and C viruses: a global overview

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3643851

Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3643851

Diagnosis, management, and treatment of hepatitis C: an update

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3643851

Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3643851

A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3643851

Treating viral hepatitis C: efficacy, side effects, and complications

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3643851

The prevalence of hepatitis C virus infection in the United States, 1999 through 2002

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3643851

Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3643851

Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3643851

Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3643851

Projecting future complications of chronic hepatitis C in the United States

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3643851

Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3643851

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3643851

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3643851

Natural history of hepatitis C: its impact on clinical management

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3643851

Interpretation of cost-effectiveness analyses

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3643851

Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3643851

Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3643851

Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3643851

Long course and prognostic factors of virus-induced cirrhosis of the liver

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3643851

Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3643851

A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C.

7 July 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-13-190

Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-13-190

Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-13-190

Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-13-190

Determinants of outcome of compensated hepatitis C virus-related cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-13-190

The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-13-190

Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-13-190

Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-13-190

Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-13-190

The burden of illness associated with hepatocellular carcinoma in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-13-190

Trends in organ donation and transplantation in the United States, 1999-2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-13-190

Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-13-190

Direct economic burden of chronic hepatitis C virus in a United States managed care population

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-13-190

Clinical outcomes after transfusion-associated hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-13-190

Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-13-190

Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-13-190

The impact of hepatitis C virus infection on work absence, productivity, and healthcare benefit costs

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-13-190

The impact of hepatitis C on labor force participation, absenteeism, presenteeism and non-work activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-13-190

The burden of untreated hepatitis C virus infection: a US patients' perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-13-190

Health-state utilities and quality of life in hepatitis C patients

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3643851

Health-State Utilities and Quality of Life in Hepatitis C Patients

26 October 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-13-190

Compensated cirrhosis: Natural history and prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-13-190

Cost Effectiveness of Peginterferon ??-2a Plus Ribavirin versus Interferon ??-2b Plus Ribavirin as Initial Therapy for Treatment-Naive Chronic Hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-13-190

Risk Factors for Hepatocellular Carcinoma among Patients with Chronic Liver Disease

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23621902

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Natural history of hepatitis C virus infection

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23621902

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/1471-2334-13-190

1 reference

Dimensions Publication ID

4 August 2017

0 references

1 reference

4 August 2017

1 reference